RECRUITING

A Trial of the Launching! to Adulthood Program

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the effectiveness of the Launching intervention (Pagan et al., 2024) in improving adaptive functioning, transition readiness, and social cognition in young adults with Autism Spectrum Disorder (ASD), compared to a delayed treatment control group, to examine whether the Launching intervention leads to improvements in executive functioning, co-occurring mental health symptoms, and quality of life, as measured by caregiver and self-report assessments, to assess the maintenance of treatment gains 12 weeks post-treatment and to replicate the findings of the Launching pilot study in an independent sample of young adults with ASD.

Official Title

A Randomized Controlled Trial of the Launching! to Adulthood Program

Quick Facts

Study Start:2025-07-15
Study Completion:2027-09-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06868537

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 25 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * confirmed case of ASD from a licensed mental health or medical professional
  2. * score of \>14 on the Social Communication Questionnaire-Lifetime (SCQ-L) completed with the mother or father
  3. * meet DSM-5 criteria for ASD based on a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) ASD symptom checklist
  4. * willing and motivated to participate in the treatment
  5. * a parent willing to participate
  6. * verbal intelligence quotient (IQ) score \>70 as assessed by the Kaufman Brief Intelligence Test 2nd edition revised (KBIT-2-R)
  1. * history of a psychotic disorder or current psychotic symptoms
  2. * suicidal ideation with intent or plan
  3. * current alcohol or other substance use disorder rated severe
  4. * concurrent enrollment in another clinical trial for autism spectrum disorder
  5. * expression of unwillingness to complete study procedures

Contacts and Locations

Study Contact

Antonio Pagan, PhD
CONTACT
(713) 486-2700
Antonio.Pagan@uth.tmc.edu
Katherine Loveland, PhD
CONTACT
(713) 486-2587
Katherine.A.Loveland@uth.tmc.edu

Principal Investigator

Antonio Pagan, PhD
PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center, Houston

Study Locations (Sites)

The University of Texas Health Science Center at Houston
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: The University of Texas Health Science Center, Houston

  • Antonio Pagan, PhD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center, Houston

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-15
Study Completion Date2027-09-01

Study Record Updates

Study Start Date2025-07-15
Study Completion Date2027-09-01

Terms related to this study

Keywords Provided by Researchers

  • Launching intervention

Additional Relevant MeSH Terms

  • Autism Spectrum Disorder (ASD)